-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MEvSFSpK1tp3KO7vYwyInKLfcmqC11F0gSnUjgeIzHmcVjv2pdr6HkyQsAK3U8hW
 hzx02SdJFfdow0Y4WxlxOg==

<SEC-DOCUMENT>0001130319-08-000465.txt : 20080530
<SEC-HEADER>0001130319-08-000465.hdr.sgml : 20080530
<ACCEPTANCE-DATETIME>20080530111543
ACCESSION NUMBER:		0001130319-08-000465
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080530
FILED AS OF DATE:		20080530
DATE AS OF CHANGE:		20080530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		08868955

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o40879e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of May 2008

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date:&nbsp;&nbsp;May 30, 2008
 </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/&nbsp;&nbsp;Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o40879o4087900.gif" alt="(ONCOLYTICS LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">210, 1167 Kensington Cr. N.W<br>
Calgary, Alberta<br>
Canada T2N 1X7</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Collaborators to Present<BR>
Reovirus Research at ASGT Meeting</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB, &#151; May&nbsp;30, 2008 </B>&#151; Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today
that two presentations covering preclinical work using the reovirus are scheduled to be delivered
by Dr.&nbsp;Richard Vile of the Mayo College of Medicine, Rochester, Minnesota, at the American Society
of Gene Therapy (ASGT)&nbsp;annual meeting in Boston, MA. The meeting runs from May&nbsp;28 to June&nbsp;1, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A poster presentation entitled &#147;<I>Combination Immunotherapy and Oncolytic Virotherapy for the
Treatment of Malignant Mesothelioma</I>&#148; is scheduled to be presented on Friday, May&nbsp;30, 2008. The
poster covers preclinical work using oncolytic viruses including reovirus against mesothelioma, a
rare but deadly cancer. <I>In vitro </I>data show that mesothelioma cells are sensitive to and support
replication of reoviruses. In addition, data suggesting how anti-tumour immunity can be enhanced
will be presented.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">An oral presentation entitled &#147;<I>Purging Lymph Node Metastases with Adoptive T Cell Therapy,
Oncolytic Virotherapy and Immunotherapy</I>&#148; is scheduled to be presented on Saturday, May&nbsp;31, 2008.
In many cancers, disease spreads to other parts of the body via the lymph nodes. In this study,
the investigators demonstrated that normal T-cells pre-loaded with reovirus localize to lymph
nodes, spleen and liver and deliver the virus to sites of metastatic disease. In addition, killing
the tumour cells in the lymph nodes and spleen by reovirus generated potent anti-tumour immunity,
preventing repopulation of the lymph nodes and spleen by further waves of cells spreading from the
primary tumour. The researchers are continuing to investigate methods of improving virus delivery,
and developing clinical protocols that will examine purging lymph nodes of tumor cells using
reovirus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Oncolytics Biotech Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit <U>www.oncolyticsbiotech.com</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication
of the materials presented at the ASGT meeting with respect to REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>, the Company&#146;s
expectations related to the results of trials investigating delivery of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>, and
the Company&#146;s belief as to the potential of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer therapeutic, involve
known and unknown risks and uncertainties, which could cause the Company&#146;s actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects,
the efficacy of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer treatment, the success and timely completion of
clinical studies and trials, the Company&#146;s ability to successfully commercialize
REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>, uncertainties related to the research and development of pharmaceuticals,
uncertainties related to the regulatory process and general changes to the economic environment.
Investors should consult the Company&#146;s quarterly</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>and annual filings with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements.</I>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" colspan="3"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top">
    <TD valign="top">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc.<br>
Cathy Ward<br>
210, 1167 Kensington Cr NW<br>
Calgary, Alberta T2N 1X7<br>
Tel: 403.670.7377<br>
Fax: 403.283.0858<br>
<U>cathy.ward@oncolytics.ca</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group<br>
Nick Hurst<br>
325, 300 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. SW<br>
Calgary, Alberta T2P 3C4<br>
Tel: 403.538.4845<br>
Fax: 403.237.6916<br>
<U>nhurst@equicomgroup.com</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group<br>
Erika Moran<br>
11 Stone St, 3rd Floor<br>
New York, NY 10004<br>
Tel: 212.825.3210<br>
Fax: 212.825.3229<br>
<U>emoran@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-30-<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o40879o4087900.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o40879o4087900.gif
M1TE&.#EA'`%``.8``)"-B_[^^_KZ^?S\_,&\J(%Z7P\,#?W]]>CGY7YW5_[^
M^GAS<MK8UO3SZOO[^F1=,\?&QJ>DB61=.L3`K?/QY&EB1;NXI/GY]JRHD_K[
M[/S]^69=0K>SFOWY^\G&LO[\_/7T\O'OZ9F3>HF#9V1@-=33NE!-365@/&IB
M.^SIWN#=U'%I2OK\^?[^]_GY\/S\^/GV];"MFOSW^92-=OS]_/S^^J.<B_S]
M\N3CTNGFW8.`?6EC-?W^_G=R3='-O,"]N5]8-?K[]>'@S/W]_=72P_+RW_[\
M^M[<RG=N4]S;Q/S^]^+@W*>CH-/2T)"*;6A>._SZ]?K\\;.NJ-K6R_SZ\>KJ
MUO;W]*2@@&9B+V=>-<[*QMC6PV%<+X1_6_K\^_G\XVED8.CFU9Z9??W[]_OY
M^_W\_6]G0?;WZL&_I'!J-&!?,VMF/??YYYR7<N_NVV57,N_NXF%8/O?V[["M
MCC,O+____O_^_O[___[__?W^_^GHV>?GT/#PX,_-LO[^_O___R'Y!```````
M+``````<`4````?_@'^"@X2%@W5UAW9^C(B.CXQ^=HE_B(:7F)F:FYR=GI^@
MH:*CI*6FHH^.>`$!=JZOKZQXJ9:GMK>XN;J[O+V;=7C!LXZPQ9./PK.^R\S-
MSL_0AHR"?@H*K79#L:S<K$,?VMK5UI33T>?HZ>KH`P-^0]\=[O!&4%,3^/GY
M36-&'^#^/KSSTVZ=P8,($X9ZU\Y!APX?C`@ID:`'B@<8,V9\TF/&%A47.LB0
MU\Z<PI,H4ZHKXVZ``R@-)A18`80$"2XV<^K<P26+A`TS1*2`,F"('P=#5"I=
MRG2747<-T"0`<G$'QAT;LFK5BH6G511/S(A)\<YHT[-HTV)BQ,J/!@UG_S@D
MV+&#Q`D)$KI$P)"CKU^_):Y,Q4NB[@@+!X+`N\.*DMK'D!4&>*&!19`;/F:\
MR7)"S8D",SPL$3!@+3P&'F(4.-$YRY,9.%AXH:$@B(+(N'.G:^M`21^+*"2<
M2,"A010Y+_SP6-ONA9(;?.94D/#`=8(I<C0$**J[N_=E-!P,:,!A#98'0)!8
M.!/$A1P\`F@DO42PN9(743PX$?X`11PQ9PP@P'S?%6B@*3QH`(<80&"!Q0EB
MP$%:44.P$%YIF,@GWQ`..'`!"!A4<,(#3TAPA1P"^''@BBQN`H\?C*4P@U5O
MJ*=$`,I%HB,F=>A85E$L$#$#"EGX%`$?"MS!P_^++3;)HE'O:"#&"0ZN8($+
MLUU2BY:.$3);!E>L($%P<S0P!`\$J>CDFM\QXH`?1""!@DTX7#"`%RSD(I\"
M+AR1P`E$3G"426P6BIMR`Z@@YA-`<.""?"\$X`@ICVCP`@L#!(%!'"CL4,`2
M/*!IZ*AH/?+'$`,L`<8*8$5P`0MO73,,I8C@T8("=M)P@1-/O%$!&"`@94<E
M6Y)J+$(M'-!"*T90$0$*:JB!`0QD^-&8+K7<00,1/:C1'P%0=*"-`K<>:^Y!
M+2SKRAAA)/``"5T(0489UDJJBS)_W"%`%!&<0,(3":0@;`#+GFMP.L&X4H<+
M<TB0!0E)G"$`&4-<F\O_-8D0%$0&(JSQ@`0C'/!*L0>7S,P=DMB!1Q7N[G!%
M$0=<4.TJ7=IRZRQ^7/"""T2L\,`:%4R!C2LF%\V,'V4DW4+#60"QQPT*0!E,
MS:?<*JF.`7@@P1HHB"!'&481:/38N:!*4!1FV-4&U'@(8NK%"N#KMAM.8!0P
MJF:1K?<M99#A@`!;K$&"!!,L2\G;N-`R"!4E`,&%&1:("\_>E)N"M``7S/!N
MP!\0K?@NM"B0@7DD8$!#.V)7KKHG[\`0`A)6%0!#Y\-.2G+BCWQ`A00XC7!!
M`')0O?KPF!QPP!`Y/$&B#^X8Q`@!<61A1A$!T*!=`&TG_4$+-RC63@`:*#``
M_QD/C?3!&`IH,$"2KN!Q#4-6!!'%&0>$^]`',IAOQT.A\H!'?>63P3_L\`&(
M%'`D^9/<`;Z0B0Z,H04%%$BZ[H`)&'3`@E#(0`8.X`#:7",`2I"#%2YPF18$
M00X*V-D!;A`J>.#O'^(:P`MJ$X33E8$&C1E"TA1P`RI`L`-V2->M'!(`9>&O
M`R$!1]+@`0.D%&50@^"!%P2PP@/`('\R"$(0-&`%+UR@BS1(5AER8`8L2(`(
M;W+>`*:P@BR@(`8XBA3V_C`O.4R``/A005%.!X^DR4`+^:#`#._0OFMD`W,7
M.``;^H!'`G#@"F@@@`>@X(`R?*`,H>H1T@S8`1=L`?^/$T"#*/&XA0R,`7/R
MR\0=)X"#SA$L216T0".3$+,!!<`:"A#`OI(0R0DLP0ID&$`4A`!*?$22`,C$
M!P%ZB4<5R+$.J$K5*AD@$'+%[1\?8(7?H'"&"?S`FS\(YP\:``4KH,H!%*0&
M?FYP`Q?<<0X)$,$=/6"<(#@`?1IP@`VHTP4X:,-Y0X!"`=SH!'<(0!9_`%L(
M*A"'NR3@""\`VSQ>@H0-2*`"0K`&(56V"E=<P`$-.((3Q"2!)Q3&+BL0@0ZT
M,(8!9-(/-NP`'))PA1X(AS5VV0!'G#"!%.@L")EH8Q;0T`([W!(/Z32$#&PP
M'0E\ZE4T<%\+\-`!,E2A6QO_0`("JBI#"U@4+WA!3W48*J(*9*4"L6D,TH9`
M`*U$P`Y&."HA!U#`#AQ`"'UP`FOV*APSC&`&`&#`!01`"#^,80IB$(%>:Y(&
MUFR@`DY0K`]N$`"D%.`B3C@`C@#:@H%F808#,`(.YYBT$&R@,W9)``Y>@!28
MWO-9*#@!#K1SAT0``WMXR$`5F!H',ZQ@#C&8PQPXP($10#8$<G`I#WHT@%LN
M809W,8,38D#=ZL[!#,)Q@@?X<(-,E!$+:+A!'6YY.T%T``HBB.T&G)`#%VB`
M!P2#3PH*4!,DZ,$A\E!`$JI+7>&2H#HCX"\&I"`%%]1`K6`C0`50L($(O.`#
M4W/%_Q`>$H(8K.`N)QB!<#$PW#"M@`FD2:,@'$"$#:QA!RN(`'7[(-P(K.#%
M"1`"96]YV1TXH07O,`@\6I"`+#Q@!@3A1MO>08$X2*`'/2"!&N(%A3)(3@%'
M*)($<-!<9=P!#THP7A56\-@5A(&=QO-ALJP!A4AE\@X:B$(#G``$O])R6?\8
MPQ@.4((1[+4';AC(<@CQ70O<0&4!T$1`V1`!(*SA,S*F08):4`4D5`!@*E`"
M#?RP"G(MZY;)RH##GA`#:X"O+0,8K28U0`!_H2`"4.A<(NSP@A>,`0X%H`[(
M,D"N`]0Z7;>9!R&6P*D'C.`+-W@!#6@0A1M$8851H,`-,O^`/3MX=@9)4I,Z
ML-?9(LT`>V?"7AT80X$1K6$.7=C!&GI`!'_H\`-3<)@$PL!11`CH`!E(0@].
ML`$1P,%PL,@F*SP=JC_XX05NZ,+65E"%,8@+FSHT+`5&L+431$`\0Z!!(59@
M4C0H8!&!;J"U&C"'G/0@"2YXP0&.T`.?%$`%D\!EW(Q!,(MRFA4;=85R&K-M
M!:"!!%C(0@2*>@P"RD$((]@!%GK0AP8X(!E(QX0*B$0")]#Z!?&AP6QH`*LH
M:!%&"GAVM`U"[6=C&[ZS8$P13K"#1GG@!#[N@0K&H`$GJV`#/F$W,&91!@<$
MH0H"KP`2IJ!9.]R!,;CL!BOZ?0?_!91``G81`14*^`U/A[H,!X">63=`H<D-
M@N)/($`KK*4)'K"$!@V(0%T`=@2>%<`F"5`!$/]P2UDM(F5&;8'+8W`S1%Q9
M`?"5U+9;</.<[UQAP9@S&A[@H#9D0``=4+G*,VZ(!F!@1"L00Q^(T(`;6"8^
M+,A^9;"N]?]QW59>QT.HM%WXL9,`!1R`PK-XT@,A1,$!'WA[W!&A[78$00@G
M>,(&$@`'!="_]1\D>#Q`07Z@!"*`<R30!XL'#I9V*UY0,5N@4V;P!$W@!011
M!H2P`CN0!01P<:N@"<HQ(/#F!$3R!"O0!PFP`0_0`SC09+:5"NY3!Z[0<B45
M`S<P5;5"_RY*HGNVTGLZQW.VT@+C(0;$1P)BX`(6]'=*N(28<`=D8`%)=GYQ
M,`,1$`%HP`<4(#];Q`+<9VUQ(VV[`7[6ACW],PNV4@0WD052D#\B0'P[T`-[
M\`(=P`!P]P![("FRP"$W$`%JX$9MP`=48(9+8@PS.(#^=@`;T"`[\`490$"N
M!#Y1P`-%T2Y9D'-2D`>2*#;?152`I@E4ERQ01P57D`4;^`9X85\FA#&P``SD
M,C0*,'LM,&D*,UY*X@?T=P"]1P(1<'&QUP)&$`(%\`">@0,N<`'*T3_(N&?2
M,!M18`$CD!7*\U\GT`-SL`7*,@8?L#X%0!<W)A\&$1X\E@5<(/\"`=`!&J`$
M2N!_8N<O)\`!UW`&5Q`MGH(#5'`$3Z!_.?`!XX4]9;`O5R"%X&(4//0%FC4T
MV#1'_M8"7:`&7;$'8Y`_'V`-$1$%\N$'<G`%RB,!4M!:8)@&9M2!"O,'KW`(
MP&"+?W<4`@`"3!`'7,`%604"K+`(5#->FD5!1F51)$![U^`VP("..'@'O&<3
M#C<0=U`#-7`#`6<5&Y`#`J1O@O>4W6`$"?0!,-``1%``"<!E.D6*:Q`#,D`0
M64<D,W`#+O6-+-!9[S(#-)"-Z*B.`6!^)V`!XJ<!1=`O0.!4;F"//Y&/XX54
M1>$")>`MTD4!1,$"-:`$N`:5;7.();#_`PSI=.+"0S>X+$/@-T2@/%:!`$[4
MD1^I+B4)"\0B-P/A!R!@`^+X4';@:<-R"003`#;YBHBGDQE7*X?YDT'Y(!%`
ME,.F``LGE$D@![,#E<*Y;ZDF`#.4+,8#!U/P`TA`=ESP!#^@0RQ@`6C7`V'P
M7F9)`3V&`J!5F31P8-OVENQH`76P)%&0`5/"!4"0`'U0(DNICU/#(4&P!SU@
M%0]U`QH03=]IE/QIE'&3,4%0`OZB!G`H'@1C-:AS`'VP-=7!(?`@-FF0!1L`
MDC,(>[4S*=2`*BEB`1=1`!00A*VP%LM"0;:B@CEI-3R)!]^I;3V(@+O("$J"
M)C#@`17`$VUP_P8P\`W8M*/#J0%!D(Z4\1:M=D5C4`1MT!-Q(`71E`/JY@,L
MH(SI0`-!X`%/X$8>\`Z8Y#\U!Y=R.028XP(N$`$D<@)M,#@;P&Y34P?OE@%]
MP#6L40(W``4!<$/]V9__Z6]!0&@G(#@1X`+-U1;O$``9M%@HT`9*F&.#,($3
M2CLSR`VVR).$\*`#P`$7D0`?FBXA2A_74%L!<`,C@@6RF:)E"`RWJ8LX]G>A
M0BURP`&\0P)SP`9&0(C9()P*0#^VIJ'CPP(7<`%N(`)%4@%:@#0#D`-PEP46
M$`10B@YA%`%X40$'4`?@@(G!<$MPR0$M@"JMMC-BL&`,.3AA4#%6YO\'\A-O
MV,4:'+`%+@`%[,1.9S`%4W`&B#D,=?`"RW8%G=&.*:`LMZ(`RN(&+O83(L`&
M.88R?/83&#"9Z0)FF!HVTC801F$!F\,'J=D6:U$#`UAXGFH3.BEQH<D#TFHM
MO$<EIDIIXN=Y$*%^>SINV"%$Z2('*C`%*F`-X;-OH;<%);`%*7!LRK)%<B`"
M>RH!EOH.*3D"55H`D6@0&G`#<4`B2.`"?O`!9""MX/,"1>8O''`#Z6@-J^!\
MCH,%:K!N!X4O[F,-+8`#,S`=(Y(`:ML#"=`%*1@'5^`&+?`(S:5F$3`7)[`"
M6%D`?%L`2#`5%5``V$%8F."193<":INX:EO_`"-`!*=3+9A@`:3HH0J#J-)@
ML7]W`%&`>!(0`[8V:1V+B;<D0PIF%SM':0$P?HR:!",0'''@MHNKMED!!EKP
M`D%@N[B"`3[6'VS;`VZ+E2/04!+@`5FHH0+`!$^P`V:P!1RK#AK@!D2R`3&0
MGTD#7Y[F!\#(MT05>-!$!B`"NP60`K>T45<F*7;@$D&``VC@!&KKMK\[!WCD
M`2E``XX`4QIR`!2@!3/`MVV[`K_;!6+@`T3Q19DP`OS;MWS;!5W`MR)P`"]@
M-IC@`5@I`@WP"I9WN5&U"@=@P`5``)^K(K4R?IY6!A*<``5@`3BR"N/7"MAT
M`UL@&`C,MX=!`!:P_P1:]!:6<@_+-`-MFP!FP+9N:X4E4$->\`$"H%`H@!,3
MD*SG$`1H``0UH@5!@'QG4@/IH@$=X``A0`%%<`9(07-_(``@Q0=8R`=!L#X;
MY3[8\#<DU`)%@(5%0`$A,,=6L$0=`@D#`#9E(`,P``(AD`)_3`1P0`$4P`=G
M`'54E`&9,,=SW`".[,A<3`&.K#XE@0D7$,E`!)KT89380P,O,,A\T`"VUCPA
M;,7I,@`7U`!R#`*+D;IH,C0"=``-P`>,[,AS?`&U82FQ`C[:$5<-$`)P``<6
M0`2,[`(WP!Y1H`3?X`?D$VY<4`%>8!`J4`$DD`4)T`",(`-D<)C*@@??8/\'
MZ,,(1".2(,1%I+$80\`^*O,^0S`;.@01Y2,`H:)+5*>K]%N21\P2\FR[K?:D
MR(=%'="/0?`%#(0)#P$14.(CQ^@'`Y)4A3!A36E4.UFQ!X8RBU`QB:$^25$K
M()1E"O`.<89-?N?*VA"3(B$2WSP$7ZE#96`$0HK#5H,F'10J,3ILBC8$2200
M2](*%D#-)#`!$34OUD0#>9`+>6#%7P@#%S`&?+@#<9D<2X(FC(`S*1,)A"!S
M#ML(,"*#?O=WKZ?0XJ#0D0`)DB#6.O*@KX<'X9,)VO#59CT(?X<)V7#1[>/0
MA1`))^EO*4,S/*E)4\T(VB"#*7.2X@P+95'5X@#_)9J$,CABU2@#HY$0*M-0
M%C$Z"PW0NER0`#E@!"Z!2QYKU!YT.DA$<H;6`RF0)'F0!V!(/*QM")4]KV?W
M`'$I,0Y`AI^-"YCH/UXZ`&%*`FO0*`>`5*F]VJU=W/DR?JL0`@('!"M0`E``
M)4J8"X?J!T8P!D*0`,*1`&$P57<PW,;]W=1@O=6C`1Y@8KX6!DX+V;D`(VRA
M`&'0!6Y4`4F0`<G1W:I=6"$``?H-`<&*(6N!-!<``59@UW?](OD-`6\]")'`
M`/N]WTW`))A@!5K0X`Q@U?0!)7_0!/H-`L1="""`X&F"`!#`X01>"B*.`#!2
MXJ=R`4W0!&4Q!$NP!/^]_R-^H.$0D-!LK2/?>0T\0`-PP&9`\`0C0`4A(0\=
M3@J2^!!0``=RXA,SX`('H";1/0@#\`,&0`<````F8`((D#J#D")#``,+8`!-
MH.*"X*4Z8`)@``!TL.404`9>\$1P710#(`59;@`&H`,`8`-VXN6#T`17GN4`
MP`1R?@D<@@!;;@!9CN*:<`<08``:.@0`8``_0"BG,.D`D.*8D"IT0.:ZI`5T
M``;_W0ZILN58#@!/=.1'X1)O\IW+TCIRL!]X8:E-!C:YH,<9)`)5:@8V(`=0
M\`X45(N$4.4&``9VX`!,@.6JWB$"8`)D;N:G,N8Z(,8@0`-@8`!2L*M(`==W
M(/\@`B(`G9X#="YBEP#H6F",(#!8*8()#M`$;?X'\[#NF>#HBJ[MDU[I1SX*
MDZX#FGX)#K`$6$X'=(``5B[J].%%`:[H*A(>("#&?DX-18$RKO[1$_8!>I``
M]XA^.<`A_FT+3C8$*C`'K"(!>R<^`_$'\`6&`F#E=*`#:9[G",#NXG$!SE[F
MFN`%UPYB?S,`^\[0S4,-P]8A+M'I2]`.`Y+O#%#L"^#R@B7OAF`%.J#H+N'P
M^9XOCPX&+K\`SH[ON8#I_6X(G,X$[FX"4A#JS#$@3"#UI&$G[8"!]-$A'0)3
M2$U7_]`"',`J6?`?*5`&JWD+.K0$3K"T*+`"/H"-X-#_/"E/"`Y0\`-`\`+?
M!&L!]S4/[=@;ZA`0`@R^`'2@!4O"'1!?>>!N`$5/+S]_"5I@`$S@X!]UY$.`
M`-<N!9</`2[>Z(\NQHQP[Y9N"CT?UX8.\$S@!Q"P`&`P_)B`-T/```*OWPBP
M!"/N^=)PX#`P<]A&.T7$`6;`!<$A`A1P/`G=#;3@"-T`V&#S:B-0$SN``CXP
M.]E`+]1`*'Z@`@(/`"ZO`R'@(GXPZ0_>\7?M!TP`"#HZ"PN"30-^?G^+BWY#
M?T,.`S`Z!@@##D-WCXR=?UIT!J(&)A>*GHR:(()T@TRHG0-#$`9#CGXV!DME
M`["^OXP`=#\#`W>_"'12?@X\_Y4+P(E#"((F)H((FKX#2ZTAOP$M&1X262A9
M$AXN02\"#AI&1C1U]/7T?AKY&B\7`OX>/=:0(+&FQ(L/IX!!<F!E$XA,VA3Z
M`2%`UC&%?P18R900V)`A`QYV_"6`HBP_5@;0P/AGX@5;(QEM&G`!1">4-#ZR
MW#E14D14S"YP='#!"B>%/")9H7BA6$Q&#D(,$?`KWP$789QL*)>EBX<B5`*4
M^?"A@YVS:-'&B_<"2@,+!5"H`2+!21\J8P0<!58,4Z2*B3`R<V>+)2:.+*=F
M0L32`420AY]Z\B/@Y<_)/!RXZ_27\4Z,G0/#^IA4EF//$@]KG@K2ER,0%U;Z
M"J"!1O^'#@A$5'B0Q9S=!@INFTV+=DB'#U#&P/'@Y(0$+&I.1.#S0H."%[(5
MGG8$$G#B2#H%#ZC8"[0D29(]@?3C]&]Z1MQ57D0UA$;%O7]RHO\,>CQJ]7W9
M$HDCADTEBRP\R+)-4.7!0ML`'9!1!AP<H/#$#KU)(((-'E``10`@A@CB!S*$
M0(`-3DCPP`-8[-!##&>\((L2001@V$F#(:;0'93)@I]K386WHT\.O)>*--(X
M)=AB1?KRT6HW0588?[^P1YAD[&'"'DB2?#=>4HO]R(A>COV"!QYU_&''!T9`
M<8$-2#PAYQ-`G',%&A/DJ6>>$4A`YQ,/K&$.!C?<H$0`9^+7H4":5#;JZ*.0
M1BKII)16"ND==RC:@@)B?3!&`QC$40$09G"!!1<KIIHJ%JP^8(8$*VP@@@H.
ML$"#B"`R:NFNO/;JZZ_`4IH'#SPH8.P+`7Q0!AE6J$#$"$B<H,9`U%8[$!!K
M((&$!RK`0`8-X'K!`Z;D!FONN>BFJVZCP_*`1P`O'#O&$+R\<,`9$UC@A+;\
M]NN$!3ZX@"P-#M`0A1(T%$,NINLV[/##$%N:B!^8!J#`NP'`-$2(&H20PL<@
<?YQ#"&5,[`<-?H03`'LT+#Q?Q##'++.Z@0``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
